Nyxoah (NASDAQ:NYXH) is a medical technology company focused on the development and commercialization of innovative solutions for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Genio™ System, is an implantable neurostimulation device designed to maintain airway patency by stimulating the hypoglossal nerve during sleep. By targeting the root cause of airway collapse, the Genio System provides a minimally invasive alternative to traditional continuous positive airway pressure (CPAP) therapy, aiming to improve patient comfort and adherence.
The Genio System employs a compact, battery-free stimulator implanted beneath the chin, paired with an external activation unit worn during sleep. This configuration allows for precise timing of nerve stimulation, synchronized with the patient’s natural breathing pattern. The device’s design emphasizes ease of implantation and maintenance, enabling physicians to perform the procedure using a simple surgical approach and reducing the need for extensive hardware management post-implantation.
Founded in 2014 and headquartered in Mont-Saint-Guibert, Belgium, Nyxoah has achieved key regulatory milestones, including CE marking in Europe and FDA approval in the United States. The company has established a presence in multiple geographies, serving sleep centers and hospitals across Europe, North America, Canada and Australia. In addition to its Belgian headquarters, Nyxoah operates offices in Boston to support U.S. clinical studies and commercialization efforts, as well as facilities in Montreal to drive research and development.
Under the leadership of Chief Executive Officer Xavier Dode, Nyxoah leverages a multidisciplinary team of engineers, clinicians and sleep medicine specialists. The company’s board and scientific advisory panel include experts in neuromodulation and respiratory medicine, guiding its strategic direction and clinical development programs. With a commitment to advancing patient-centric solutions, Nyxoah continues to expand its clinical evidence and support network to bring neurostimulation therapy to patients affected by OSA worldwide.
